Abstract Metastasis suppressor genes (MSGs) have contributed to an understanding of regulatory pathways unique to the lethal metastatic process. When re-expressed in experimental models, MSGs block cancer spread to, and colonization of distant sites without affecting primary tumor formation. Genes have been identified with expression patterns inverse to a single MSG, and found to encode functional, druggable signaling pathways. We now hypothesize that common signaling pathways mediate the effects of multiple MSGs. By gene expression profiling of human MCF7 breast carcinoma cells expressing a scrambled siRNA, or siRNAs to each of 19 validated MSGs (NME1, BRMS1, CD82, CDH1, CDH2, CDH11, CASP8, MAP2K4, MAP2K6, MAP2K7, MAPK14, GSN, ARHGDIB, AKAP12, DRG1, CD44, PEBP1, RRM1, KISS1), we identified genes whose expression was significantly opposite to at least five MSGs. Five genes were selected for further analysis: PDE5A, UGT1A, IL11RA, DNM3 and OAS1. After stable downregulation of each candidate gene in the aggressive human breast cancer cell line MDA-MB-231T, in vitro motility was significantly inhibited. Two stable clones downregulating PDE5A (phosphodiesterase 5A), an enzyme involved in the regulation of cGMP-specific signaling, exhibited no difference in cell proliferation, but reduced motility by 47 and 66 % compared to the empty vector-expressing cells (p = 0.01 
and p = 0.005). In an experimental metastasis assay, two shPDE5A-MDA-MB-231T clones produced 47-62 % fewer lung metastases than shRNA-scramble expressing cells (p = 0.045 and p = 0.009 respectively). This study demonstrates that previously unrecognized genes are inversely related to the expression of multiple MSGs, contribute to aspects of metastasis, and may stand as novel therapeutic targets.
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Introduction
In 2013, an estimated 232,340 new cases of invasive breast cancer were expected to be diagnosed among women and approximately 39,620 women were expected to die from breast cancer in the US [1] . Despite improvements in surgery, radiation and chemotherapy, metastatic disease remains the most common contributor to breast cancerrelated mortality [2] . Treatment methods developed by focusing on the primary tumor eventually fail in many cases, and metastatic disease remains incurable. Thus, to increase survival, metastasis prevention and more effective treatments for established metastases are necessary.
The metastasis suppressor gene (MSG) family includes genes that, when re-expressed in a metastatic tumor cell, are able to inhibit the metastatic process without reducing primary tumor size. Often, MSGs are downregulated in the metastatic site compared to the primary tumor [3] . Since the discovery in 1988 of the first metastasis suppressor, NM23-H1 (or NME1), the number of confirmed MSGs has increased to over 30 [3] [4] [5] [6] [7] [8] . MSGs are involved in cellular processes such as context-specific cellular proliferation, motility, adhesion, invasion, resistance to apoptosis, and angiogenesis. Understanding the biological mechanisms of the MSGs will be crucial to developing treatments that target this process. To date, studies have almost universally concentrated on one specific MSG, rather than investigating commonalities.
Attempts to therapeutically target MSG pathways have been proposed (reviewed in [9] ). The identification of drugs that reactivate silenced MSGs has been reported [10] [11] [12] [13] . An inverse correlation approach was successfully used to identify new druggable targets to each of two MSGs, RHOGDI2 (ARHGDIB) and NM23 [14, 15] . By reexpressing RHOGDI2 in metastatic bladder cancer cells and identifying transcripts repressed by RHOGDI2 and overexpressed in invasive bladder tumors, Titus et al. [15] discovered both endothelin-1 and neuromedin-U; atrasentan, an inhibitor of endothelin-1, is a new therapeutic agent. For NM23-H1, Horak et al. discovered that LPAR1 (EDG2/ LPA1), a lysophosphatidic acid receptor, was inversely expressed. Re-expression of LPA1 overcame NM23-H1 inhibition of motility and metastasis [14, 16] . Pharmacologic LPA1 inhibition resulted in significantly reduced metastasis formation with induction of cancer cell dormancy at the metastatic sites in in vivo models [17] .
Although MSGs appear to have different cellular localizations and functions, pathway interrelationships and redundancies are beginning to emerge [18, 19] . Berger et al. [7] described the involvement of three MSGs, NM23, MAP2K4 and PEBP1 (RKIP) in two biochemically interconnected Map kinase signaling pathways, MAPK/ERK and JNK signaling. It is likely that multiple common signaling pathways are used by the MSGs, and that some of these pathways can represent interesting translational targets for the development of antimetastatic strategies. We present herein a first gene expression analysis of multiple MSGs: AKAP12 (SSeCKS/GRAVIN) [20] , ARHGDIB [21] , BRMS1 [22] , CASP8 [23] , CD44 [24, 25] , CD82 (KAI-1) [26, 27] , CDH1 [28, 29] , CDH2 [30] , CDH11 [31] , DRG1 [32] , GSN [33] , KISS1 [34] , MAP2K4 [35] , MAP2K6 [36] , MAP2K7 [37] , MAPK14 (p38-a) [36] , NME1 (NM23/NDPK), PEBP1 [38] , and RRM1 [39] . We have identified and validated five genes: DNM3, OAS1, IL11RA, UGT1A, and PDE5A as having expression patterns inverse to at least five (and up to 11) MSGs. As proof of principle, when the expression of each gene was silenced using shRNAs, in vitro motility of MDA-MB-231T cells was decreased. PDE5A was upregulated in eight of nineteen siRNA-MSG samples. The stable silencing of PDE5A in MDA-MB-231T cells using two different shRNAs reduced experimental metastasis by 47 and 62 %, respectively.
Materials and methods
Cell culture conditions
Human breast cancer cell lines MCF7 and BT474, and immortalized kidney cell line HEK293TN were obtained from ATCC (Manassas, VA, USA). BT474-M1 subline was obtained from MC Hung, MD Anderson Cancer Center, TX, USA [40] . A sub-line of human MDA-MB-231 cells, designated MDA-MB-231T, was used [10] . Cells were cultured in Dulbecco's Modified Eagle Medium (DMEM) (Invitrogen, Grand Island, NY, USA) supplemented with 10 % FBS, and antibiotics (100 U/ml penicillin, 100 lg/ml streptomycin; Invitrogen), under a humidified 37°C incubator at 5 % CO 2 .
Gene silencing
RNAi's were purchased from Qiagen (Valencia, CA, USA, Supplementary Table S1 ) and transfected into MCF7 cell line using Lipofectamine TM RNAiMax (Invitrogen) according to the manufacturer's protocol. Briefly, either 2 9 10 6 or 1 9 10 6 cells were plated in 100-mm petri dishes and incubated for either 48 or 96 h, respectively, with 30 nM siRNAs and 30 ll Lipofectamine RNAiMax. These two time points were chosen in order to analyze both the early (48 h) and late (96 h) effects of the MSGs silencing in terms of alteration in downstream gene expression.
To stably knockdown the target genes' expression in MDA-MB-231T cells, Mission-shRNA (Sigma, St. Louis, MO, USA) were used and insertion into the cells was performed using lentiviral particle production and infection according to the manufacturer's protocol. Briefly, 1 9 10 6 HEK293TN cells were transfected with 1 lg each of shRNA-MSG plasmids and 2 ll packaging mix (Clontech, Montain View, CA, USA) using 3 ll FuGENE HD transfection reagent (Roche, Indianapolis, IN, USA). After 48 h incubation, the medium containing the newly formed viral particles was collected, filtered with Millex-HV 0.45 lm filters (Millipore, Carrigtwohill, CO, USA) and added to 1 9 10 6 MDA-MB-231T cells together with 5 lg/ml polybrene solution (Sigma). After 24 h infection, cells were washed with PBS, and DMEM containing 1 lg/ml Puromycin (Invitrogen) was added to select the infected cells. The following Mission-shRNA plasmids were used: pLKO (SHC001), NT (SHC216), shPDE5A (TRCN0000048743, TRCN0000048745), shDN M3 (TRCN0000051405, TRCN0000051407), shOAS1 (TRC N0000005007, TRCN0000005009), shUGT1A1 (TRCN000 0029530, TRCN0000029531), shUGT1A9 (TRCN0000034 655, TRCN0000034656).
Microarray analysis siRNA-MSG transfected MCF7 cells were collected at 48 and 96 h using TRIzol Reagent method (Invitrogen). RNA was extracted using RNeasy Ò mini Kit (Qiagen, Valencia, CA, USA) and DNase I (Qiagen) following manufacturer's instructions.
The RNA concentration was assessed using Nanodrop ND-1000 spectrophotometer (ThermoScientific, Wilmington, DE, USA). RNA quality was measured by calculating RNA integrity number on Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).
Following quantification, 1 lg of total RNA was used for microarray analysis and sent to Affymetrix Core Service (NIH, Frederick, MD, USA) where labeling and hybridization reactions were performed using standard Affymetrix protocols. The platform used was the Affymetrix-Genechip Human Genome-U133_Plus_2.0 Array. Expression values were calculated using Affymetrix GeneChip analysis software MAS 5.0. Microarray data can be obtained via the Gene Expression Omnibus repository, accession no. GSE53668. Probes of selected genes are listed in Table 1 and Supplementary Table S2 .
Quantitative Reverse-Transcription-Polymerase Chain Reaction (qRT-PCR) Expression of MSGs or selected target genes was measured by qRT-PCR. Total RNA was extracted as described above. cDNA was synthesized using iScript TM cDNA synthesis Kit (Bio-Rad, Hercules, CA, USA). One lg total RNA was added to the reaction mix (1 ll iScript reverse trancriptase, 4 ll 59 reaction mix, nuclease-free water to 20 ll final volume). The mixture was incubated at 25°C for 5 min, 42°C for 30 min, 85°C for 5 min and 4°C until use. cDNA (10 ng) was used as template with primers (Sigma, listed in Supplementary Table S3 ) and SYBR Green (Bio-Rad) for qRT-PCR using an iQ5-detection system (Bio-Rad) following manufacturer's instructions. Expression levels of the genes were normalized to GAPDH levels. Results were analyzed using iQ5-Optical System software (Bio-Rad).
Cloning and gene overexpression IL11RA cDNA was obtained from pOTB-IL11RA plasmid (ATCC, MGC-2146) and subcloned into a lentiviral pCDH-CMV-MCS-EF1-NEO vector (CD514B-1, System Biosciences, Mountain View, CA, USA) using EcoRI and XhoI restriction sites. Lentiviral particles were prepared as described above and MCF7 cells were infected for 48 h and selected with neomycin (1 mg/ml).
Western blot analysis
Protein lysates were prepared as previously reported [16] . Membranes were probed over-night at 4°C with the following rabbit polyclonal antibodies: anti-IL11RA (Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-UGT1A1 (Abcam, Cambridge, MA, USA), anti-OAS1 (Abcam), anti-PDE5A (Abcam), anti-DNM3 (ProteinTech, Chicago, IL, USA). Mouse anti-ß-Actin antibody (Sigma) was used as loading control.
Cell migration assay
Transwell migration assays were performed in Boyden chambers as previously described [16] . Each condition for all cell lines was assayed in triplicate wells and each experiment was performed in triplicate.
Cell proliferation assay Cellular proliferation was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. 1,000 cells/well were plated in 96 well plates and grown for 24, 48 and 72 h prior to the addition of 10 % MTT (Sigma). After 2 h incubation, MTT was solubilized by addition of 100 ll/well of DMSO. Plates were incubated for 30 min at 37°C and read on a SpectraMax M2 plate reader (Molecular Devices, Sunnyvale, CA, USA) at 570 nm.
Experimental pulmonary metastasis mouse model Experiments were performed under an approved National Cancer Institute (NCI) Animal Use Agreement. Female 6-week-old athymic nude mice were obtained from Charles River Laboratories (NCI-Frederick Animal Production Area, Frederick, MD, USA). 5 9 10 5 MDA-MB-231T cells were injected into the lateral tail vein of each mouse [10] . A total of 10 mice/experimental group was used. At week 9, mice were sacrificed and lungs collected in Bouin's solution (70 % picric acid, 25 % Formaldehyde, 5 % glacial acetic acid). Surface lung metastatic lesions were counted before paraffin-embedding and sectioning (10 lm) the tissues. Hematoxylin and Eosin (H&E) staining was performed to visualize and count the metastatic lesions in each section. To measure proliferation rate in metastasis, lungs were stained with rabbit anti-Ki67 antibody (Vector 
The ''-1'' and ''-2'' indicate independent siRNAs # Distance between the two samples in units of standard deviation Laboratories, Burlingame, CA, USA), following manufacturer's protocol.
Bioinformatic and statistical analysis
Differential gene expression analysis of the microarray dataset was performed using R software (http://www.rproject.org). ANOVA method was applied to calculate a t statistic value for relative difference in gene expression based on permutation analysis. Ingenuity Pathway Systems (Redwood City, CA, USA; http://www.ingenuity.com) was used to conduct pathway exploration. The significance of mean comparison was assessed by either Student's t test or Mann-Whitney test and considering 95 % confidence interval. p \ 0.05 was considered to be significant.
Validation of the inverse correlation between the selected genes and MSGs in breast tumor cohort was performed analyzing the microarray expression data from two publicly available datasets downloaded from NCBI GEO: GSE2034 and GSE1456 [41, 42] . The two datasets include 286 and 159 breast cancer patients, respectively. Partek Genomics Suite (http://www.partek.com) was used to perform the statistical analysis. The expression data were median-centered and log 2 -transformed for each gene across all samples. For each gene of interest, the expression values were averaged and plotted on a bar chart. A third publicly available dataset was used for the Pearson correlation analysis: GSE26304 [43] . This dataset includes 31 pure DCIS, 36 IDC patients, 42 mixed and 6 normal samples.
Results
Inverse association approach to identify downstream targets to multiple MSGs
Based on the success of previous studies identifying functional, druggable inverse correlates of single tumor suppressors or MSGs [14, 15] , we hypothesized that genes with expression patterns inverse to that of multiple MSGs exist and could provide functional and therapeutic insights into the metastatic process. For this analysis, each of 19 MSGs was silenced in vitro and gene expression profiled. The tumorigenic cell line MCF7 was chosen to study the effect of MSG downregulation on gene expression. The expression of each MSG in MCF7 cell line was first verified using qRT-PCR ( Supplementary Fig. 1 ). Most of the MSGs showed a relatively high expression level with NME1 having the highest expression and AKAP12 the lowest expression level of the genes analyzed. Independent transfections of MCF7 cells were performed using two different siRNA sequences targeting each MSG (Supplementary Table S1 ) or a siNeg-siRNA. RNA was harvested 48 and 96 h post siRNA transfection and the silencing of each MSG was assessed by qRT-PCR compared to either wild type (wt) or siNeg-siRNA transfected cells (Fig. 1) . Because of variability in siRNA-knockdown efficiencies, especially for poorly expressed genes (CDH2, AKAP12, KISS1), data obtained from the two siRNAs were pooled together. To identify genes differentially expressed following silencing of each MSG, we conducted microarray analysis of RNA samples from both the 48 and 96 h MSG siRNA transfected MCF7 cells and control cells (wt and siNeg-siRNA).
Identification of candidate genes inversely associated to multiple MSGs Affymetrix HG-U133_Plus_2.0 was chosen for gene expression profiling. This platform allows the analysis of over 47,000 transcripts. A total of 77 gene chips were used to analyze the samples. Differentially expressed genes were defined using a combined analysis of the expression profiles of siRNA transfectants of all 19 MSGs versus the six control samples (three wt and three siNeg) at both time points. At 48 h, 257 genes and at 96 h, 419 genes were upregulated in the pool of siRNA-MSGs samples as compared to control samples with a t-statistic (distance between two samples in units of standard deviation) [2 and p \ 0.01 (Supplemental Tables S4 and S5 ). Ingenuity pathway analysis identified 6 major biological functions in common between the upregulated genes at 48 and 96 h: cell morphology, cell signaling, metabolism, proliferation, development and immune signaling (Fig. 2) . Eighteen upregulated genes were selected for further validation based on: (a) t-statistic larger than 2 and (b) p value smaller than 0.01 in at least one of the two time points.
In vitro validation of the inverse association between selected genes and MSGs
The inverse correlation between the expression of multiple MSGs and the selected candidate genes was validated in an independent set of siRNA-MSGs MCF7 transfections using qRT-PCR. Similar to the microarray analyses, target gene expression in siRNA-MSG and siNeg transfected cells were compared at 48 and 96 h post siRNA transfection. Upregulation of at least 1.5-fold as compared to the control was observed for UGT1A, OAS1, DNM3, IL11RA, PDE5A, BCAR4, CA9, WNK3, TXNRD1, and MMP16 following silencing of five or more MSGs (Fig. 3, Supplementary  Fig. 2 ). In contrast, the upregulation of LPXN, TARP, APH1B, CXCR7, CYP4V2, SRMS, NRIP3, and CNTNAP4 was validated for less than five MSGs ( Supplementary  Fig. 2 ).
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Five candidate genes (UGT1A, DNM3, OAS1, IL11RA, and PDE5A) were selected for further analysis based on their p values, their occurrence in common pathways shown in Fig. 2 and drug-target suitability (Table 2) . In order to assess their association with cell migration ability, each of these five candidate genes was stably silenced in the aggressive human breast cancer cell line MDA-MB-231T using two specific shRNAs and subsequent cell motility was evaluated (Fig. 4) . Validation of shRNA silencing was conducted using western blotting.
UGT1A (UDP-glucoronosyltransferase-1 family) was upregulated at 48 h (t-stat = 2.77, p = 0.01) from the siRNA-MSG transfection in the microarray analysis (Table 1) . Using qRT-PCR, UGT1A expression was at least 1.5-fold upregulated by the knockdown of eleven genes (AKAP12, BRMS1, CD44, CD82, CDH11, DRG1, GSN, MAP2K4, MAP2K6, MAP2K7, PEBP1) (Fig. 3a) . The UGT1A locus encodes several isoforms of the UDPglucoronosyltransferase 1 family of proteins involved in the glucoronidation of xenobiotics and endogenous compounds [44] . The probe set used for the microarray was unable to distinguish between the specific isoforms. Our study focused on UGT1A1 and UGT1A9 isoforms as they were expressed in MDA-MB-231T cells ( Supplementary  Fig. 3 ) and were previously evaluated in relation to breast cancer [45, 46] . MDA-MB-231T cells were stably transfected with shRNA specifically targeting either UGT1A1 or UGT1A9 (Fig. 4a) . Western blot analysis showed UGT1A1 downregulation in two MDA-MB-231T cell clones, #30 and 31. UGT1A9 downregulation in the two stable clones (#55 and 56) was evaluated using qRT-PCR due to low expression in this cell line. Although the transfection of the shRNA scramble (NT) caused a minor reduction in UGT1A1/9 expression as compared to the empty vector expressing cells (pLKO), cell migration of these two controls was not affected. Motility assays showed a significant reduction in cell migration of clones expressing shUGT1A1 (64 %, p = 0.003 and 71 %, p = 0.0004) and shUGT1A9 (56 %, p = 0.004 and 86 %, p = 0.001) as compared to the control cells (Non-target, NT). No difference in cell proliferation was observed (Supplementary Fig. 4a ). DNM3 encodes Dynamin-3, a member of a family of GTPases associated with microtubules and involved in vesicular transport and endocytosis [47] . DNM3 was also upregulated at 48 h (t-stat = 2.52, p = 0.01) following the silencing of MSG genes (Table 1) . Validation by qRT-PCR showed at least a 1.5-fold upregulation of DNM3 following silencing of six MSGs (CASP8, CD44, CD82, CDH1, GSN, MAP2K4) (Fig. 3b) . The stable silencing of DNM3 (clones #05 and 07; Fig. 4b) Fig. 4b ). 2 0 -5 0 -oligoadenylate synthetase-1 (OAS1) encodes a member of the 2-5 synthetase family involved in the innate immune response to viral infection [48] . This gene was upregulated at 48 h (t-stat = 2.82, p = 0.01) and at 96 h (t-stat = 2.88, p = 0.01) from the siRNA-MSG transfection in the microarray analysis ( Table 1 ). The qRT-PCR validation experiment showed at least a 1.5-fold OAS1 upregulation by six MSGs (ARHGDIB, CD44, CD82, CDH11, MAP2K4, MAP2K7) (Fig. 3c) . After transfection of two shRNAs targeting OAS1, the two stable clones #07 and 09 showed a reduction in OAS1 expression by Western blot and a trend in reducing cell motility as compared to the NT cells (26.5 %, p = 0.02 and 32 %, p = 0.08 respectively) (Fig. 4c) . No difference in cell proliferation was observed ( Supplementary Fig. 4c) .
IL11RA encodes the a-subunit that, together with gp130, forms IL11 receptor [49] . It was upregulated in the microarray analysis at 48 h (t-stat = 2.18, p = 0.04) and at 96 h (tstat = 5.69, p \ 0.001) from the siRNA-MSG transfections ( Table 1 ). The qRT-PCR validation showed at least a 1.5-fold increase of IL11RA expression upon knockdown of eleven MSGs (ARHGDIB, BRMS1, CDH1, MAP2K4, MAP2K6, MAP2K7, MAPK14, PEBP1, RRM1) (Fig. 3d) . As IL11RA expression in MDA-MB-231T was too low to be downregulated, overexpression of either IL11RA or the empty vector was performed in MCF7 cell line (Fig. 4d) . The two IL11RA overexpressing clones, #2 and 3, showed a 2.1-(p = 0.0008) and 1.4-(p = 0.04) fold increase in cell migration as compared to the vector expressing cells. The overexpression of IL11RA in the MCF7 induced a reduction in cell proliferation at a 72 h time point (p = 0.03 and 0.01) as compared the control sample (Vector 1) (Supplementary Fig. 4d ).
In the microarray analysis, phosphodiesterase-5A (PDE5A), the gene encoding for the enzyme involved in the regulation of cGMP [50] , was upregulated at 48 h (tstat = 1.99, p = 0.05) and at 96 h (t-stat = 4.77, p \ 0.001) from siRNA-MSG transfection ( Table 1 ). The qRT-PCR validation showed at least a 1.5-fold PDE5A upregulation by knockdown of eight MSGs (ARHGDIB, BRMS1, CASP8, CD44, CDH2, MAP2K4, MAPK14, PEBP1) (Fig. 3e) . Two shRNA sequences silenced PDE5A expression in MDA-MB-231T cells, creating stable clones #43 and #45 (Fig. 4e) . Both shPDE5A_43 and shPDE5A_45 clones with silenced PDE5A expression showed a significant reduction in cell migration (47 %, p = 0.01 and 66 %, p = 0.005, respectively) as compared to the shRNA negative control (NT). No difference in cell proliferation was observed between the stable clones as compared to either the empty vector (pLKO)-or scramble-shRNA transfectants ( Supplementary Fig. 4e ). To further investigate the inverse association of PDE5A expression with metastatic property, PDE5A protein levels were measured in BT474 cells and a metastatic sub-clone BT474-M1 [40] . PDE5A expression was higher in the highly metastatic BT474-M1 cells than in the low metastatic BT474 cell line ( Supplementary Fig. 5 ).
In summary, using microarray analysis and qRT-PCR, we identified and validated several candidate genes whose expression was inversely associated to multiple MSGs in the breast cancer cell line, MCF7. The in vitro data demonstrate that the selected candidates, DNM3, OAS1, UGT1A, IL11RA and PDE5A, were able to affect cell migration to various degrees when silenced (DNM3, OAS1, UGT1A, PDE5A) or overexpressed (IL11RA) in metastatic breast cancer cells. The data demonstrate that common downstream signaling pathways link multiple MSGs. Many of these common networks are either new, or not well studied in the metastasis field. The data also provide a first comprehensive gene expression analysis upon MSGs downregulation. PDE5A, being a known druggable target [51] , was selected for further investigation. To investigate the role of PDE5A in metastasis formation in vivo, MDA-MB-231T breast cancer cells expressing shRNA-PDE5A (clone #43 and #45), empty vector or negative control shRNA were injected into tail veins of athymic nude mice. 9 weeks post-injection, the lungs were collected and fixed in Bouin's solution. Metastases visible on the surface of the lungs were counted (Fig. 5a ). Both PDE5A silenced clones reduced metastasis (clone #43 median = 15, p = 0.0006 and clone #45 median = 42, p = 0.043) as compared to the control sample (median = 64.5), which included both the empty vector and shRNA-negative cells. The lungs were then paraffin-embedded and sectioned for further analysis. H&E staining confirmed that the number of lung metastases in both shPDE5A_43 (median = 14. Fig. 4 UGT1A, DNM3 samples was significantly reduced when compared to the control sample (median = 38) (Fig. 5b, c) . To assure that the observed phenotype was a result of a direct influence on the metastatic process rather than an effect on the growth rate of the cells, cell proliferation was measured in the lung metastatic lesions using Ki67 staining (Fig. 5d, e) . No difference in the number of Ki67-positive cells was observed in the metastatic lesions between the experimental groups. The data show that PDE5A, inversely associated to eight MSGs at 96 h of siRNA-MSG transfection, functionally participated in cell motility in vitro and metastasis in vivo.
Validation of inverse correlation between PDE5A and 8 MSGs in human breast cancer cohorts
The inverse association between PDE5A and the identified MSGs was further validated in two human breast cancer gene expression cohorts: GSE2034 and GSE1456 [41, 42] . The datasets included 286 and 159 breast carcinoma samples, respectively. Partek Genomics Suite was used to evaluate the correlation in terms of expression of PDE5A with the set of 8 MSGs (ARHGDIB, BRMS1, CASP8, CD44, CDH2, MAP2K4, MAPK14, PEBP1). The mean expression value for the probe set of each gene was plotted in a bar graph for each dataset (Fig. 6 ). When PDE5A expression was compared to the MSGs, PDE5A was significantly inversely correlated to the 8 identified MSGs in both human breast cancer cohorts (p = 0.003 in GSE2034 and p = 0.03 in GSE1456; Table 3 ).
The association between DNM3, IL11RA, OAS1, UGT1A and their respective inversely expressed MSGs was also investigated in the same human breast cancer cohorts. DNM3 expression showed a significant inverse correlation to its MSGs set (CASP8, CD44, CD82, CDH1, DRG1, GSN, MAP2K4) with p = 0.02 in both breast cancer cohorts. UGT1A and OAS1 showed a trend toward an inverse correlation to their respective MSGs sets, while no significant correlation was found for IL11RA and its MSGs set (Table 3) .
A third human breast cancer gene expression cohort (GSE26304) was used to perform Pearson correlation coefficient analysis for PDE5A. This dataset includes 115 samples with different stages of breast cancer (31 pure DCIS patients, 36 IDC patients, 42 mixed and 6 normal) and is thus suited for this analysis. PDE5A showed an inverse correlation to all of 8 MSGs included in the analysis (Table 4) .
Discussion
It has been argued that the metastatic process, in contrast to conventional wisdom, is a ripe target for therapeutic development, as it widely contributes to cancer patients' deaths [52] , although new clinical trial designs will be needed for validation [53, 54] . Multiple MSGs have been discovered in model systems. Through apparently different pathways, based on the gene-by-gene literature, they lead to the same biological event: suppression of metastasis formation. Since suppressor genes are virtually impossible to directly and uniformly deliver, we and others have focused on downstream pathways, herein transcripts with opposite, presumed pro-metastatic expression patterns. We present the first comprehensive analysis of the downstream transcriptional effects of MSG expression, and identify several common gene expression pathways of functional and potential therapeutic significance.
Nineteen MSGs were transiently downregulated, each by two siRNAs at two tissue culture time points in MCF7 breast carcinoma cells. MCF7 cells were chosen as a line expressing relatively high levels of 10 of the 19 genes and, consistent with high MSG expression, exhibiting a relatively low tumor cell motility phenotype. While a good system for this analysis, not all of the MSGs have been validated as functional in this line, and the transcriptional analysis was conducted on tissue culture plastic, which may vary from in vivo patterns. The two siRNAs sometimes failed to knock down gene expression to identical levels. Despite these caveats, and using a simple bioinformatics process, several upregulated genes were identified comparing the gene expression profile of siRNAMSGs and the control samples. Inversely related genes were chosen on the basis of their upregulation in five or more siRNA-MSGs, t-statistic and p value (p \ 0.01). Many of the remaining genes had interesting but less statistically significant gene expression trends, suggesting that their transcriptional effects may still be of interest. The raw gene expression data can be used for additional, potentially more sophisticated analyses of MSGs function.
Our analysis identified 257 genes at 48 h and 419 genes at 96 h inversely associated with multiple MSGs expression. Ingenuity Pathway analysis showed that six major pathways were affected by multiple MSGs silencing: cell morphology, proliferation, metabolism, development, cell signaling and immune signaling. Eighteen genes were chosen for validation by qRT-PCR using independent cultures. Functional experiments were conducted in an independent cell line, MDA-MB-231T, to test the generality of the observations. Several of the identified genes, or their gene families, have been recognized in the metastasis literature. The current analysis suggests the widespread relevance of these genes to metastasis via their transcriptional regulation by multiple MSGs. Other genes were new to the metastasis literature.
The dynamin family is involved in membrane trafficking processes such as vesicle scission at the plasma membrane or trans-Golgi network, phagocytosis, cytokinesis, podosome formation, and endocytosis [47, [55] [56] [57] [58] [59] . DNM2 upregulation has been linked to increased motility and metastasis in a pancreatic model system [58] , and inhibitors have been identified [60] . DNM3 is normally expressed in neurons, testis and megakaryocytes. Little is known about a role of DNM3 in cancer. Herein we demonstrate a trend of reduced tumor cell motility in vitro when DNM3 was inhibited by shRNAs in metastatic MDA-MB-231T cells.
Similarly, 2 0 -5 0 -oligoadenylate synthetase-1 (OAS1) encodes a well characterized enzyme involved in the innate immune response to viral infection [48] . After its induction by interferons, OAS1 activates RNase L, which degrades viral and cellular RNA and inhibits replication and protein synthesis suppressing viral growth and promoting apoptosis [61] . The only link of OAS1 to cancer is found in polymorphisms associated with prostate cancer [62, 63] . Herein, downregulation of OAS1 by two shRNAs in MDA-MB-231T cells resulted in a trend of decreased cell motility in vitro. The partial effects of gene knockdown on tumor cell motility may deserve additional experimentation as they were interrogated in only one cell line and may have significant combinatorial effects.
The IL11RA gene encodes the a-subunit that, together with gp130, forms the receptor for the cytokine IL11, a member of the IL-6 family. Its activation induces JAK-STAT and MAPK signaling cascades [49] . IL11Ra expression was associated with tumor progression in prostate, ovarian, gastric, hepatocellular and breast cancers, and with tumor invasion and lymphatic infiltration in colorectal carcinomas [64] [65] [66] [67] . Herein, overexpression of IL11RA significantly increased tumor cell motility in vitro and exerted limited effects on proliferation of MCF7 cells. It should be pointed out that these last two candidates are both involved in the immune response. Immune signaling was a major pathway affected by MSGs silencing.
In contrast to these genes, the identification of UGT1A transcripts as being both inversely expressed with multiple MSGs and functionally contributory to motility is, to our knowledge, completely unexpected. UDP-glucoronosyltransferases are membrane-bound enzymes, localized in the endoplasmatic reticulum, that catalyze the glucoronidation of various endogenous and exogenous compounds such as bilirubin, bile acids, steroid hormones, chemotherapeutics, non-steroidal anti-inflammatory drugs, anticonvulsants. Eighteen UGT transcripts have been identified and divided in three families UGT1A, UGT2A and UGT2B based upon sequence homology [68] . The UGT1 family includes nine functional proteins (A1, A3-10) and four pseudogenes derived from alternative splicing of a single gene locus [69] . The several UGT1A isoforms show different tissue expression patterns, with only UGT1A9 localized in breast [46] . Several members of the UGT1A family, such as UGT1A1 and UGT1A9, are involved in the conjugation of estradiol and its hydroxylated and/or methylated metabolites [70] . Polymorphic variants of UGT1A1 and UGT1A9, highly expressed in liver, have been widely studied for their influence on irinotecan metabolism and toxicity [71, 72] . Although UGT1A polymorphisms and their functional consequences appear to play important role in cancer risk and response to therapy, their direct influence in cancer progression remains to be characterized. Herein we demonstrate that the downregulation of both UGT1A isoforms, UGT1A1 and UGT1A9, in the ER-negative, metastatic cell line MDA-MB-231T resulted in reduced cell motility, suggesting a potential role in this process.
A functional role for phosphodiesterase type-5A (PDE5A), which was inversely associated with 8 MSGs, was tested both in motility assays and in an in vivo metastasis assay. In addition, the inverse correlation of PDE5A and the 8 MSGs (ARHGDIB, BRMS1, CASP8, CD44, CDH2, MAP2K4, MAPK14, PEBP1) was validated in three human breast cancer cohorts. The datasets included microarray data from primary tumor samples, and the expression of PDE5A was very low. It would be interesting to analyze potential inverse correlation in metastatic biopsies in the future, where we expect a reduction in expression of the MSG and a consequent increase in PDE5A expression.
Phosphodiesterases are intracellular enzymes that hydrolyze cyclic adenosine and guanosine monophosphates (cAMP and cGMP) to their respective 5 0 -nucleoside monophosphate. There are 11 PDE families with different substrate specificities, regulatory properties, tissue localizations, and inhibitor sensitivities (reviewed in [73, 74] ). Through alternative splicing, the PDE5A gene generates three PDE5 isoforms, PDE5A1-3 [73] . PDE5 is a cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase [50] , involved in regulation of apoptosis [75] [76] [77] , synaptic plasticity [78] , platelet aggregation [79] , and fluid secretion in intestinal cells [80] . PDE5 inhibitors, sildenafil (Viagra Ò ) and vardenafil (Levitra Ò ) are FDA-approved drugs used for erectile dysfunction [51, 81] . In preclinical experiments they increase chemotherapeutic sensitivity to many, but not all drugs tested [82] [83] [84] [85] [86] [87] . A role for PDE5 or its pharmacologic inhibitors in metastasis has been reported in lung colonization by melanoma cells [88] . Herein, PDE5A was described for the first time as a downstream target of multiple MSGs. PDE5A downregulation in metastatic breast cancer cells resulted in reduced cell motility and lung metastasis formation in experimental metastatic models. Although cGMP is an important second messenger in cell signaling, how PDE5A modulates signaling pathways in the context of metastasis in still unclear and should be a topic of further investigation.
How the MSGs regulate PDE5A expression is another question of interest. Ingenuity pathway analysis of PDE5A and the 8 inversely correlated MSGs suggested a functional connection between PDE5A and MSGs mediated by PP1-C (protein phosphatase 1) and IL1b (interleukin 1beta) ( [89, 90] and data not shown). Although lacking significant p values, both PP1-C and IL1b were also present in our MCF7 microarray dataset, with PP1-C being downregulated (48 h: t-stat = -0.72, p = 0.47; 96 h: t-stat = -1.47, p = 0.14) and IL1b upregulated (48 h: t-stat = 1.91, p = 0.06; 96 h: t-stat = 1.51, p = 0.14). The data suggest an indirect regulatory effect on PDE5A by MSGs, mediated by PP1-C and IL1b.
The data demonstrated only a partial (47-62 %) reduction in metastasis formation by downregulation of PDE5A, suggesting that the anti-metastatic effects of multiple MSGs may be mediated by multiple factors/pathways. It would be interesting to evaluate the metastatic properties of tumor cells upon knocking down the expression of a combination of the inversely correlated genes identified in this study. In summary, the data suggest that genes inversely correlated to multiple MSGs may contribute to tumor cell migration and may represent the new focus in the investigation of metastasis-related pathways.
